COOKIES: By using this website you agree that we can place Google Analytics Cookies on your device for performance monitoring. |
University of Cambridge > Talks.cam > Combinatorics Seminar > Shadows and intersections: stability and new proofs
Shadows and intersections: stability and new proofsAdd to your list(s) Download to your calendar using vCal
If you have a question about this talk, please contact Andrew Thomason. We give a short new proof of a version of the Kruskal-Katona theorem due to Lov\’asz. Our method can be extended to a stability result, describing the approximate structure of configurations that are close to being extremal, which answers a question of Mubayi. This in turn leads to another combinatorial proof of a stability theorem for intersecting families, which was originally obtained by Friedgut using spectral techniques and then sharpened by Keevash and Mubayi by means of a purely combinatorial result of Frankl. We also give an algebraic perspective on these problems, giving yet another proof of intersection stability that relies on expansion of a certain Cayley graph of the symmetric group, and an algebraic generalisation of Lov\’asz’s theorem that answers a question of Frankl and Tokushige. This talk is part of the Combinatorics Seminar series. This talk is included in these lists:
Note that ex-directory lists are not shown. |
Other listsThe Sackler Lectures PMP Presentation Day Future of Sentience CambridgeOther talksCyclic Peptides: Building Blocks for Supramolecular Designs Radiocarbon as a carbon cycle tracer in the 21st century Requirements in Application Development Predictive modeling of hydrogen assisted cracking – a Micromechanics conquest Prof Kate Jones (UCL): Biodiversity & Conservation Adaptive auditory cortical coding of speech The Anne McLaren Lecture: CRISPR-Cas Gene Editing: Biology, Technology and Ethics Genomic Approaches to Cancer "Mechanosensitive regulation of cancer epigenetics and pluripotency" 'Walking through Language – Building Memory Palaces in Virtual Reality' Validation & testing of novel therapeutic targets to treat osteosarcoma |